Roche and Molecular Partners have entered into a research and licensing alliance to discover, develop and commercialize new cancer treatments. The agreement will incorporate Molecular Partners ...

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...

Roche's pharmaceutical portfolio now includes ... The company plans to advance four new molecular entities with potential launches in 2026. Near Patient Care remains a strategic focus, supported ...

“Rapid molecular point-of-care testing can revolutionise ... said Matt Sause, CEO Roche Diagnostics. More than 1 million people worldwide acquire an STI every day. Common STIs often present ...